Alteogen ALT-B4-based ‘Jemperli SC’ heads into clinical trials, GSK signals November start
GSK is advancing a subcutaneous version of its drug Jemperli, using Alteogen's ALT-B4, into clinical trials starting November. The Phase 1b/3 trial will enroll 380 patients with advanced endometrial cancer. GSK licensed ALT-B4 from Alteogen in January 2026 for USD 285 million in potential milestones. Jemperli generated GBP 861 million in 2025 sales. Alteogen's ALT-B4 is also used in MSD's Keytruda SC, which generated USD 463 million in Q2 2026.
How this was made
The 30-second read
Why it matters
The partnership may accelerate market adoption and generate new revenue streams if clinical data are positive.
Market read
First disclosure of a major licensing deal and trial start, relevant for oncology and biotech investors.
What to watch
Regulatory timelines and potential competition from other ALT‑B4 partners could limit upside.
Background
GSK is expanding its immuno‑oncology portfolio by converting Jemperli to a subcutaneous format using Alteogen's ALT‑B4 platform.
Ticker impact
GSK disclosed a $20M upfront licensing deal with Alteogen for ALT-B4 and announced the start of a Phase 1b/3 trial of Jemperli SC on Nov 12.
likely upward pressure as investors price in potential revenue from a subcutaneous Jemperli formulation.
New partnership and trial start represent a material catalyst for GSK's oncology pipeline.
Market effects
May boost the subcutaneous formulation segment and encourage similar deals across pharma.
Highlights South Korean biotech's role in global drug development.
Adds to the pipeline of immuno‑oncology assets, relevant for oncology investors worldwide.
Counterpoint
If the SC formulation fails to show superiority, the deal could be a sunk cost and weigh on GSK.
Key entities
- pharmaceutical companyGlaxoSmithKline
US‑listed drugmaker launching Jemperli SC trial.
- biotech companyAlteogen
Korean firm providing the ALT‑B4 hyaluronidase platform.
